![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pharnext’s Charcot-Marie-Tooth Disease Treatment Gets Fast Tracked
Pharnext’s Charcot-Marie-Tooth Disease Treatment Gets Fast Tracked
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/Pharnext_Logo.gif?t=1549668226&width=430)
The FDA granted a fast track designation to Pharnext’s Pleodrug PXT3003, a treatment for Charcot-Marie-Tooth disease.
The French drugmaker’s twice-daily, novel synergistic drug — a combination of naltrexone, sorbitol and baclofen — is in development to treat Type 1A of the disease, a rare chronic neuropathy that currently has no approved treatment. The condition affects at least 125,000 individuals in the U.S. and Europe.
The company’s Phase 3 PLEO-CMT trial, a 15-month double blind study, met the FDA and EMA’s primary endpoint of overall neuropathy limitation scale and exhibited a statistically significant difference when compared to placebo.
Upcoming Events
-
21Oct